Publicacións en colaboración con investigadores/as de Charité (135)

2024

  1. Consensus on criteria for acromegaly diagnosis and remission

    Pituitary, Vol. 27, Núm. 1, pp. 7-22

  2. Correction: consensus on criteria for acromegaly diagnosis and remission (Pituitary, (2024), 27, 1, (7-22), 10.1007/s11102-023-01360-1)

    Pituitary

  3. Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023

    Nature Medicine

  4. Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

    Microorganisms, Vol. 12, Núm. 4

2023

  1. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

    Annals of the rheumatic diseases, Vol. 82, Núm. 5, pp. 698-709

  4. Corrigendum to “Dissecting the genetic heterogeneity of gastric cancer” (eBioMedicine (2023) 92, (S2352396423001810), (10.1016/j.ebiom.2023.104616))

    eBioMedicine

  5. Dissecting the genetic heterogeneity of gastric cancer

    eBioMedicine, Vol. 92

  6. Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))

    Nature communications

  7. High-content multimodal analysis supports the IL-7/IL-7 receptor axis as a relevant therapeutic target in primary Sjögren's syndrome

    Journal of Autoimmunity

  8. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 936-955

  9. Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

    Pituitary, Vol. 26, Núm. 5, pp. 583-596

  10. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK

    Schizophrenia Research

2022

  1. After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181

  2. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

    Pharmacopsychiatry, Vol. 55, Núm. 2, pp. 73-86

  3. Development and validation of the food allergy severity score

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 5, pp. 1545-1558

  4. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  5. Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia

    Microorganisms, Vol. 10, Núm. 4

  6. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366